%0 Generic
%A Delgado-Fernandez, Marcial
%A Garcia-Gemar, Gracia Mar
%A Fuentes-Lopez, Ana
%A Munoz-Perez, Manuel Isidro
%A Oyonarte-Gomez, Salvador
%A Ruiz-Garcia, Ignacio
%A Martin-Carmona, Jessica
%A Sanz-Canovas, Jaime
%A Castano-Carracedo, Manuel Aangel
%A Reguera-Iglesias, Jose Maria
%A Ruiz-Mesa, Juan Diego
%T Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature
%D 2022
%@ 0213-005X
%U https://hdl.handle.net/10668/26025
%X Patients lacking humoral response have been suggested to develop a less severe COVID-19, but there are some reports with a prolonged, relapsing or deadly course. From April 2020, there is growing evidence on the benefits of COVID-19 convalescent plasma (CCP) for patients with humoral immunodeficiency. Most of them had a congenital primary immunodeficiency or were on treatment with anti CD20 antibodies. We report on three patients treated in our hospital and review thirty-one more cases described in the literature. All patients but three resolved clinical picture with CCP. A dose from 200 to 800 ml was enough in most cases. Antibody levels after transfusion were negative or low, suggesting consumption of them in SARS-CoV-2 neutralization. These patients have a protracted clinical course shortened after CCP. CCP could be helpful for patients with humoral immunodeficiency. It avoid relapses and chronification. CCP should be transfused as early as possible in patients with COVID-19 and humoral immunodeficiency.(c) 2021 Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica. Published by Elsevier Espana, S.L.U. All rights reserved.
%K Covid-19
%K Convalescent plasma
%K Humoral immunodeficiency
%K Rituximab
%K Obinutuzumab
%K Coronavirus disease 2019
%K Liver-transplant recipients
%K Rituximab
%K Sars-cov-2
%K Therapy
%K Antibodies
%K Mechanism
%K Outcomes
%~